Pathology & Laboratory Medicine

Warning message

Selective filter "Related Faculty (field_biblio_faculty) (selective)" has limited the amount of total results. Please, review you query configuration.

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Zuckerman AL, Pourvaziri A, Ebb DH, Boyraz B. Case 26-2023: A 15-Year-Old Girl with Abdominal Pain and an Ovarian Mass. N Engl J Med. 2023;389(8):750-758.

Aguilar R, Khan L, Arslanovic N, Birmingham K, Kasliwal K, Posnikoff S, et al. Multivalent binding of the tardigrade Dsup protein to chromatin promotes yeast survival and longevity upon exposure to oxidative damage. Res Sq. 2023.

Zhang T, Kutler D, Scognamiglio T, Gudas LJ, Tang X-. Transcriptomic analysis predicts the risk of progression of premalignant lesions in human tongue. Discov Oncol. 2023;14(1):24.

Rozental O, Cushing MM, Shander A, Isbister JP, Lasocki S, Meybohm P, et al. Penny-wise and pound-foolish: the challenges of preoperative anaemia management. Br J Anaesth. 2023;131(2):214-221.

Metzler VM, de Brot S, Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, et al. The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer. Front Cell Dev Biol. 2023;11:1116424.

Maura F, Ziccheddu B, Xiang JZ, Bhinder B, Rosiene J, Abascal F, et al. Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells. Blood Cancer Discov. 2023;4(3):208-227.

Panarelli NC, Hornick JL, Yantiss RK. What Is the Value of Counting Mast Cells in Gastrointestinal Mucosal Biopsies? Mod Pathol. 2023;36(2):100005.

Medford AJ, Oshry L, Boyraz B, Kiedrowski L, Menshikova S, Butusova A, et al. TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis. Ther Adv Med Oncol. 2023;15:17588359231152844.

Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, et al. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. J Transl Med. 2023;21(1):75.

Hagemann IS, Bridge JA, Tafe LJ, Hameed MR, Moncur JT, Bellizzi AM, et al. Current Laboratory Testing Practices for Assessment of ERBB2/HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma. Arch Pathol Lab Med. 2023;147(10):1148-1157.